These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1983011)

  • 1. Development of dopaminergic drugs for the chronic treatment of congestive heart failure.
    Casagrande C; Merlo L; La Regina A
    J Auton Pharmacol; 1990; 10 Suppl 1():s85-93. PubMed ID: 1983011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New dopamine agonists in cardiovascular therapy].
    Girbes AR; Van Veldhuisen DJ; Smit AJ
    Presse Med; 1992 Aug 29-Sep 5; 21(27):1287-91. PubMed ID: 1359528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure.
    Hasenfuss G; Just H
    Basic Res Cardiol; 1989; 84 Suppl 1():191-6. PubMed ID: 2573341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine agonists, a new perspective in cardiovascular therapy?
    Girbes AR; van Veldhuisen DJ; Smit AJ
    Neth J Med; 1991 Aug; 39(1-2):65-71. PubMed ID: 1683693
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of dopaminergic agents and the dopamine receptor in treatment for CHF.
    Carey RA; Jacob L
    J Clin Pharmacol; 1989 Mar; 29(3):207-11. PubMed ID: 2566626
    [No Abstract]   [Full Text] [Related]  

  • 6. Dopamine and dopamine receptor agonists in cardiovascular therapy.
    Murphy MB; Elliott WJ
    Crit Care Med; 1990 Jan; 18(1 Pt 2):S14-8. PubMed ID: 1967161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with intravenous fenoldopam.
    Holcslaw TL; Beck TR
    Am J Hypertens; 1990 Jun; 3(6 Pt 2):120S-125S. PubMed ID: 1974440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dopaminergic agents on cardiac and renal function in normal man and in patients with congestive heart failure.
    van Veldhuisen DJ; Girbes AR; de Graeff PA; Lie KI
    Int J Cardiol; 1992 Dec; 37(3):293-300. PubMed ID: 1361484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of dopamine receptors in the treatment of congestive heart failure.
    Goldberg LI
    J Cardiovasc Pharmacol; 1989; 14 Suppl 5():S19-27. PubMed ID: 2478806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular and renal action of dopaminergic prodrugs.
    Casagrande C; Merlo L; Ferrini R; Miragoli G; Semeraro C
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S40-59. PubMed ID: 2483441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapeutic profile of ibopamine in heart failure.
    Taylor SH
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S118-23. PubMed ID: 2483437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the acute hemodynamic effects of ibopamine and dopamine in chronic congestive heart failure.
    Sannia L; Ibba GV; Castellaccio M; Dore L
    Arzneimittelforschung; 1986 Feb; 36(2A):355-9. PubMed ID: 3707649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure.
    Spencer C; Faulds D; Fitton A
    Drugs Aging; 1993; 3(6):556-84. PubMed ID: 7906158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT).
    van Veldhuisen DJ; Man in 't Veld AJ; Dunselman PH; Lok DJ; Dohmen HJ; Poortermans JC; Withagen AJ; Pasteuning WH; Brouwer J; Lie KI
    J Am Coll Cardiol; 1993 Nov; 22(6):1564-73. PubMed ID: 7901256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic evaluation of ibopamine in patients with refractory congestive heart failure.
    Humar F; Morgera T; Maras P; Camerini F
    Arzneimittelforschung; 1986 Feb; 36(2A):360-2. PubMed ID: 3707650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine.
    Metra M; Missale C; Spano PF; Cas LD
    J Cardiovasc Pharmacol; 1995 May; 25(5):732-40. PubMed ID: 7630152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitored long-term treatment with ibopamine in patients suffering from severe congestive heart failure.
    Avanzini Z; Bellogini GC; Brusoni B; Ciampani N; Dei Cas L; Gazzola U; Maggi GC; Mangiavacchi M; Metra M; Pinca L
    Arzneimittelforschung; 1986 Feb; 36(2A):394-7. PubMed ID: 3707656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopaminergic drugs in the management of chronic heart failure.
    Pouleur H; Raigoso J; Rousseau MF
    Eur Heart J; 1991 Aug; 12 Suppl C():29-34. PubMed ID: 1680685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels.
    Rajfer SI; Rossen JD; Douglas FL; Goldberg LI; Karrison T
    Circulation; 1986 Apr; 73(4):740-8. PubMed ID: 3948372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular pharmacology of adrenergic and dopaminergic receptors: therapeutic significance in congestive heart failure.
    Lokhandwala MF; Hegde SS
    Am J Med; 1991 May; 90(5B):2S-9S. PubMed ID: 1675549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.